• DAWN Trial: Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

    In 2015, five major randomized controlled trials showed that thrombectomy for anterior large vessel ischemic strokes within 6 hours provided benefit. What about patients who present beyond 6 hours? The DAWN a multicenter, prospective, randomized, open-label, blinded endpoint trial was designed to study thrombectomy in stroke patients who present within 6-24 hours, have a small MRI or CT perfusion core and clinical deficit out of proportion to imaging. Key inclusion criteria were: last known well 6-24 hours, mismatched clinical deficit and infarct defined in 3 groups (Group A: age >80, NIHSS >10, infarct volume <21; Group B: age <80, NIHSS >10, infarct volume <31 and Group C: age <80, NIHSS >20, infarct volume 31-51) and CT or MR angiogram evidence of ICA terminus and/or M1 occlusion. Eligible patients were randomized 1:1 to thrombectomy plus standard medical care or to standard medical care alone. Only 1 stent-retriever was permitted and rescue reperfusion therapy with other devices was not allowed. The trial was stopped prematurely at 31 months for superiority of thrombectomy. Both endpoints favored thrombectomy: 1) mean mRS disability score (0=death, 10=no symptoms) at 90 days was 5.5 vs 3.4; 2) functional independence rate (mRS of 0-2) at 90 days was 49% vs 13%. All secondary endpoints also favored thrombectomy and safety was similar. Overall, this study suggests that for every 2.8 patients who underwent thrombectomy 1 additional patient had functional independence at 90 days. 


    New England Journal of Medecine

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy